Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a histologically or cytologically confirmed malignant solid tumour.~* Progression or recurrence of the tumour radiologically established or confirmed within the 4 weeks prior to inclusion.~* Disease must be considered refractory to any line of conventional therapy or for which no effective conventional treatment exists.~* Age: ≥4 to 21 years of age at study entry~* Life expectancy: at least 8 weeks~* ECOG Performance status ≤ 1 or Lansky-Play Scale ≥ 70%~* Written informed consent of parent/guardian and patient assent~* Wash out of 4 weeks in case of prior chemotherapy, 6 weeks if treatment included nitrosoureas, 2 weeks in case of vincristine alone; 6 weeks in case of prior radiotherapy (except palliative radiotherapy on non measurable lesions).~* Patients must have recovered from the acute toxic effects of all prior therapy before enrolment into the study~* Able to comply with scheduled follow-up and with management of toxicity~* All patients with reproductive potential must practice an effective method of birth control while on study.~* Female patients aged \> 12 years must have a negative pregnancy test within 7 days before study treatment.~* Capable of swallowing oral medication~Exclusion Criteria:~* Pregnant and breast feeding women.~* Uncontrolled intercurrent illness or active infection~* Inability to swallow oral medication.~* Patients on anticonvulsants will be allowed on study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- traetment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).